Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ...
Curanex Pharmaceuticals, Inc. CURX on Thursday said it is expanding its drug development pipeline. Pipeline Expansion Adds ...
Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...
Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...
This schematic illustration shows the major organs that are affected by and contribute to the development of pancreatic cancer cachexia. With pancreatic cancer at the center of the crosstalk network, ...
MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...
Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...
Reimagining Cancer Care for Patients Experiencing Homelessness by Expanding the Traditional Oncology Team Cachexia is a systemic wasting syndrome prevalent in patients with cancer that significantly ...
Up to 80 percent of patients with cancer struggle with cachexia, often called wasting syndrome, which is a condition characterized by the inability to gain or maintain body weight. One of the reasons ...
The optimal therapy for anorexia and cachexia is curing the underlying cancer. [23] Unfortunately, this goal is often not attainable with currently available treatments. Thus, an integrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results